Key findings

  • Level IImoderate evidence for knee osteoarthritis, acute or chronic neck pain, temporomandibular disorders and pain, edema and trismus after third-molar extraction
  • Level IVvery low evidence for painful diabetic neuropathy, vulvo-perineal pain and primary headaches
  • 2 to 10 J/cm²the range validated clinical windows generally cover, depending on the condition
  • 90% to 95%of incident light the skull can absorb or scatter in transcranial treatment of headaches

Abstract

Background
Pain management in non-cancer pathologies represents a major public health challenge due to its chronic nature, functional impact, and the limitations or side effects of long-term systemic therapies. As a direct sequel and clinical complement to our companion review focusing on oncology supportive care, photobiomodulation—defined as the therapeutic use of non-ionizing and athermal light radiation within the red and near-infrared spectrum—emerges as a promising non-pharmacological modality to attenuate musculoskeletal, neuropathic, and orofacial symptoms outside the cancer field1–5.
Objective
This narrative review aims to critically evaluate the clinical efficacy of photobiomodulation in managing non-cancer pain, completing our global evaluation of light-based analgesia by providing clear guidance regarding dosimetric parameters, clinical consensus frameworks updated to 2026, and current methodological limitations in the literature.
Method
A narrative review of the literature was conducted. The sources consulted primarily included the PubMed, PubMed Central, and Cochrane databases for clinical publications extending up to September 2026. The selection criteria focused on randomized controlled trials (RCTs), systematic reviews, meta-analyses, and international consensus guidelines (such as the World Association for light Therapy - WALT) addressing non-oncological painful conditions.
Results
The strongest evidence supports the clinical efficacy of photobiomodulation for knee osteoarthritis, acute and chronic neck pain, temporomandibular disorders, and acute post-operative complications (pain, edema, trismus) following third-molar extraction6–15. Recent data from late 2025 and 2026 confirm that results appear promising but remain preliminary or highly variable for fibromyalgia, burning mouth syndrome, carpal tunnel syndrome, pelvic pain, and painful diabetic neuropathy16–29. Pronounced protocol heterogeneity across studies (variations in wavelengths, power, irradiance, and treatment frequencies) accounts for the divergence of certain clinical outcomes.
Limitations
The main weaknesses of the current literature reside in the variable methodological quality of trials, small sample sizes for emerging indications, a high risk of blinding bias in chronic syndromes, incomplete reporting of physical parameters, and a lack of rigorous standardization across equipment manufacturers1,2,27–33.
Conclusion
Expanding upon our previous oncological findings, photobiomodulation constitutes a useful tool in the multimodal analgesic strategy for non-cancer pain, provided it is delivered within validated therapeutic windows and ideally combined with active physical rehabilitation. The clinical message calls for caution: efficacy must not be overstated for complex systemic syndromes, and parameters must be strictly tailored to anatomical depth barriers.

Introduction

Photobiomodulation (PBMT) attracts growing interest in the field of physical medicine and pain management but also elicits a certain degree of mistrust. Presented at times empirically or confused with surgical lasers that exert thermal and ablative effects, this technique has historically suffered from a lack of clarity. It is, however, not new: first described in the late 1960s under the name of low-level laser therapy (LLLT), it has since been reclassified under the term photobiomodulation to include non-coherent sources such as light-emitting diodes (LEDs). It is defined by the application of low power densities in the red and near-infrared spectrum (600 to 1100 nanometers), triggering photochemical rather than thermal effects.

This review is designed as a direct sequel and necessary expansion of our first article, which exclusively critically evaluated photobiomodulation within supportive oncology care (addressing oral mucositis, radiodermatitis, lymphedema, and chemotherapy-induced neuropathies). By moving outside the oncological scope, the current paper completes our global overview of light therapy, addressing the massive clinical challenges of benign chronic pain management. For the pain physician managing non-cancer conditions, the stakes remain concrete: having a non-invasive, low-iatrogenic approach that can potentially reduce medication load, improve functional mobility, and mitigate reliance on systemic analgesics, particularly nonsteroidal anti-inflammatory drugs (NSAIDs) and opioids3–5.

Brief Overview of Analgesic Mechanisms

The biological effect of photobiomodulation is initially based on the absorption of photons by intracellular chromophores, chief among which is mitochondrial cytochrome c oxidase (CCO). This photon absorption (specifically in the red and near-infrared bands) induces a conformational change in the enzyme that lifts the competitive inhibition exerted by nitric oxide (NO) on this active site. Once NO is photodissociated, the mitochondrial respiratory chain is reactivated, the mitochondrial membrane potential increases, and adenosine triphosphate (ATP) synthesis is stimulated.

At controlled therapeutic doses, the transient modulation of reactive oxygen species (ROS) acts as an essential second messenger, activating key transcription factors such as nuclear factor-kappa B (NF-κB) or nuclear factor erythroid 2-related factor 2 (Nrf2), thereby initiating cytoprotective and antioxidant cascades. Conversely, at excessive doses, this production induces deleterious oxidative stress, which explains the biphasic nature of the biological response dictated by the Arndt-Schulz law.

Recent preclinical immunological data from 2026 demonstrate that pulsed near-infrared photobiomodulation can also reactivate local T-lymphocyte immunity without structural tissue toxicity, thus updating our classic understanding of cellular tolerance. Several interconnected pathophysiological pathways contribute to analgesia in musculoskeletal and neurogenic disorders3–5:

  • Reduction of local inflammation: Direct modulation of pro-inflammatory cytokine expression (such as TNF-α, IL-6, and IL-1β) within joint spaces, tendon sheaths, and peri-articular tissues.
  • Hemodynamic optimization: Improvement of local microcirculation and lymphatic drainage, promoting the clearance of algogenic mediators (bradykinin, serotonin) and reducing inflammatory edema.
  • Direct neuronal action: Inhibitory effect on the nociceptive system through reversible mitochondrial changes and a decrease in available ATP within dorsal root ganglion (DRG) neurons.

These combined mechanisms reversibly slow down or block electrical conduction in small-diameter afferent nerve fibers (C and Aδ fibers), disrupt fast axonal transport, and decrease the release of substance P and CGRP, thereby providing a robust mechanistic rationale for its deployment in routine clinical practice.

Review Methods and Search Strategy

To ensure a rigorous and transparent approach to the clinical literature on non-cancer pain management, a structured search strategy was implemented. This methodology was designed to identify high-quality clinical evidence while minimizing selection bias.

Search databases and strategy

A systematic search of the literature was conducted across the PubMed, PubMed Central (PMC), and Cochrane Database of Systematic Reviews for articles published up to September 2026. The search syntax combined Medical Subject Headings (MeSH) terms and relevant free-text keywords using Boolean operators (AND, OR). The primary search blocks were structured as follows:

  • Modality terms: "photobiomodulation", "photobiomodulation therapy", "low-level laser therapy", "LLLT", "low-intensity laser", "cold laser", "light-emitting diode therapy", "LED therapy".
  • Clinical target terms: "pain management", "chronic pain", "musculoskeletal pain", "knee osteoarthritis", "neck pain", "low back pain", "fibromyalgia", "diabetic neuropathy", "temporomandibular disorders", "burning mouth syndrome", "carpal tunnel syndrome", "post-operative pain", "third-molar extraction".

The search was limited to peer-reviewed articles published in English and French. Reference lists of all retrieved systematic reviews and meta-analyses were manually screened to identify additional relevant trials.

Inclusion criteria

  • Study Design: Randomized controlled trials (RCTs), prospective cohort studies, systematic reviews, meta-analyses, and official consensus frameworks or clinical guidelines issued by international scientific societies (such as the World Association for light Therapy - WALT).
  • Population: Adult patients (aged ≥ 18 years) presenting with primary or secondary non-cancer painful conditions, including degenerative joint diseases, mechanical spinal pain, non-oncological neuropathies, orofacial pain syndromes, and acute post-surgical models.
  • Intervention: Therapeutic application of non-ionizing, athermal light radiation within the visible red (600–700 nm) or near-infrared (700–1100 nm) spectrum, utilizing coherent (laser) or non-coherent (LED) sources.
  • Outcomes: Documented objective or subjective pain metrics (e.g., Visual Analog Scale [VAS], Numerical Rating Scale [NRS]), functional recovery indexes, or total rescue analgesic consumption.

Exclusion criteria

  • Oncological Pain: All studies addressing pain directly related to active tumor proliferation, cancer-related bone metastases, or side effects induced by anticancer therapies (fully covered in our companion paper).
  • Experimental Data: Purely in vitro laboratory studies, animal models, and preclinical biochemical evaluations, except when strictly cited to clarify fundamental bioenergetic analgesic mechanisms.
  • Methodological Redundancy: Case reports, small retrospective series (fewer than 10 patients), letters to the editor, book chapters, and meeting abstracts.
  • Inadequate Physical Reporting: Clinical trials that completely omitted critical dosimetric and optical metrics (wavelength, power output, irradiance, fluence, or exposure duration).
  • Thermal Invalidation: Studies utilizing high-intensity lasers or light configurations that induced macroscopically detectable tissue heating, structural denaturation, or photothermal ablation.

Clinical Indications in Non-Cancer Pain Management

Outside oncology, the clinical picture is more mixed: signals of efficacy are real, but heterogeneity regarding populations, devices, and physical parameters is more pronounced, making dosimetric rigour all the more critical for the clinician. Most of the indications detailed below rest on moderate to preliminary levels of evidence.

Musculoskeletal pain

Typology and Methodology. The literature on musculoskeletal disorders is vast but qualitatively uneven. Knee osteoarthritis represents one of the most extensively studied indications, backed by multiple systematic reviews and meta-analyses aggregating over thirty randomized controlled trials (RCTs). These trials typically contrast active laser or LED configurations against a visual and acoustic sham device. Primary endpoints primarily focus on pain reduction via the VAS and functional improvement using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Follow-up periods generally span from 4 weeks to 6 months. For neck pain, a landmark meta-analysis compiled data from over 820 patients. In contrast, data regarding low back pain, disc herniation, and tendinopathies rely on smaller, often monocentric cohorts (30 to 80 patients) where active irradiation is evaluated as an adjunct therapy alongside standard physical therapy or eccentric exercise protocols30–32.

Strength of Evidence. Umbrella reviews and aggregated evidence from late 2025 classify the level of evidence as Level II (moderate recommendation) for knee osteoarthritis and acute or chronic neck pain, provided specific treatment frameworks are strictly respected6–8. Conversely, the strength of evidence drops to Level III (low certainty/insufficient evidence) for mechanical low back pain, disc herniation, and various upper or lower limb tendinopathies, where it appears mainly as a possible optional adjunct to exercise30–32.

Heterogeneity and Contradictory Results. Pronounced protocol heterogeneity accounts for the divergence of certain clinical outcomes. Wavelengths vary significantly between the visible red spectrum (650 nm) for superficial tendons and the near-infrared spectrum (810 to 904 nm) required to reach deep joint spaces or spinal structures. Documented fluences range wildly from underpowered applications (0.5 J/cm²) to excessive thermal doses, illustrating the therapeutic risk associated with the biphasic dose-response curve. Clinical contradictions are frequent: several high-quality trials reveal a complete absence of long-term superiority over a sham treatment in chronic low back pain.

Furthermore, a frequent paradox appears in tendinopathy trials where lower reported immediate pain scores do not consistently translate into accelerated tissue healing or long-term functional recovery. This clear dissociation highlights a critical clinical concept: immediate analgesic success must not be mistakenly equated with rapid structural remodeling of the extracellular matrix.

Fibromyalgia

Typology and Methodology. The current literature relies on a modest number of systematic overviews aggregating between 5 and 12 randomized controlled trials, representing a modest total cohort of 250 to 500 patients. Active irradiation—frequently utilizing wide-field LED panels or multi-diode cluster probes to cover multiple tender points—is evaluated either as a monotherapy or combined with supervised aerobic exercise. Evaluation criteria track changes in widespread pain scores, sleep disturbances, fatigue, and the global impact on quality of life via the Fibromyalgia Impact Questionnaire (FIQ). Tracking typically spans 4 to 12 weeks post-treatment.

Strength of Evidence. In systematic reviews updated in 2026, the level of evidence is considered Level III (promising but insufficient evidence). The results are encouraging regarding short-term pain mitigation and FIQ score improvement, but they await large-scale confirmation.

Heterogeneity and Contradictory Results. Protocols vary drastically between localized point-by-point laser applications over specific cervical or lumbar trigger points and whole-body photobiomodulation beds. Wavelengths combine red and near-infrared bands with fluences ranging from 2 to 10 J/cm² per site. The main conflict in the literature lies in the modest sample sizes and high risk of blinding bias due to the systemic nature of the disease. Efficacy vanishes or decreases significantly when PBMT is not coupled with physical exercise, making it difficult to isolate the specific biostimulative effect from the overall therapeutic benefits of active conditioning. Consequently, for generalized central sensitization syndromes, peripheral light distribution must serve purely as a functional facilitator for aerobic reconditioning rather than a standalone curative modality.

Non-cancer neuropathic pain

Typology and Methodology. Painful diabetic peripheral neuropathy (DPN) represents the primary model studied within this category. Systematic reviews aggregate data from small-scale clinical trials (30 to 60 patients per cohort) contrasting near-infrared limb applications against a sham device. Primary endpoints evaluate sensory thresholds, neuropathic symptoms via the Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) scale, and subjective burning pain. Follow-up is short, rarely exceeding 12 weeks. Preclinical data show accelerated axonal regeneration and a plausible mechanistic rationale regarding mitochondrial potential restoration in dorsal root ganglion cultures.

Strength of Evidence. The level of evidence is graded as Level IV (very low / contradictory data). Efficacy is currently not established by systematic reviews due to parametric scattering.

Heterogeneity and Contradictory Results. The diffuse anatomical nature of the nerve deficits requires large boots or panels operating in the deep infrared spectrum (810 to 980 nm). A major recurring paradox appears in the literature: despite a highly plausible biological mechanism, clinical trials have yielded highly variable and contradictory results. While some 2026 clinical investigation protocols describe a significant subjective reduction in numbness, high-quality systematic reviews conclude that there is a complete lack of firm, reproducible clinical demonstration, highlighting a prominent gap between biological plausibility and clinical reality in non-cancer neuropathic conditions.

Recent data from the NEUROLIGHT 2026 trial stress that curative effects remain deeply dependent on optimizing treatment frequency and localized biometric variations. Clinicians must remain fully aware that nerve structures display unique bioenergetic absorption parameters; standard musculoskeletal guidelines cannot be applied interchangeably to metabolic neuropathies without risking complete therapeutic invalidation.

Orofacial pain

Typology and Methodology. This section encompasses temporomandibular disorders (TMD), burning mouth syndrome (BMS), and trigeminal neuralgias. For TMD, meta-analyses aggregate 10 to 20 trials tracking joint pain and maximal mouth opening9–11. For BMS, the literature is more robust, featuring a recent meta-analysis of fourteen RCTs compiling data from approximately 550 patients19–21. Active intraoral irradiation is contrasted against standard topical treatments (clonazepam, hyaluronic acid) or a placebo. Endpoints track burning sensations on a VAS and specific quality of life modules. Follow-up ranges from 4 weeks to 6 months. Trigeminal and orofacial post-herpetic neuralgias rely only on preliminary data or isolated case series.

Strength of Evidence. Comprehensive 2026 datasets classify the level of evidence as Level II (moderate evidence) for short-term pain relief and functional jaw improvement in TMD9–11. It sits at Level III (promising evidence) for localized burning reduction in BMS19–21. Conversely, the level of evidence drops to Level IV (very weak evidence) for acute trigeminal neuralgia and post-herpetic sequelae.

Heterogeneity and Contradictory Results. Treating the oral cavity requires specialized endocavitary probes or precise contact laser pens. Protocols fluctuate between visible red (630 nm) for mucosal burning and near-infrared (810 nm) to reach deep joint capsules or nerve branches. Substantial heterogeneity in parameters generates conflicting results: in burning mouth syndrome, while a significant reduction in burning pain is documented (standardized mean difference of approximately −0.87), analyses reveal a complete absence of significant effect on the patients' overall quality of life scores. This gap highlights that local mucocutaneous stabilization cannot fully overwrite the complex psychological and central neuropathic burden of chronic idiopathic orofacial pain. Efficacy is also highly operator-dependent, with late initiation or incorrect probe angulation leading to immediate therapeutic failure.

Other indications

Vulvo-perineal Pain. Data regarding provoked vestibulodynia and chronic pelvic pain rely on small pilot RCTs and observational cohort studies where photobiomodulation is delivered via specialized endocavitary vaginal probes23–26. Mid-2026 data report marked improvement in mucosal local pain and sexual function parameters, opening new pathways for supportive gynecological care. However, these encouraging pilot steps currently lack long-term multicentric validation and suffer from small cohort constraints, keeping this indication firmly at a preliminary evaluation stage.

Carpal Tunnel Syndrome. Meta-analyses aggregate 5 to 10 trials evaluating short-term wrist conduction and local discomfort27–29.

Third-Molar Extraction Surgery. Serving as an excellent acute post-surgical pain model, multiple meta-analyses aggregate over 15 trials tracking post-operative complications12–15. Endpoints evaluate objective jaw trismus (inter-incisal distance), facial edema via facial metering, and total rescue analgesic consumption up to day 7.

Headaches. Data are restricted to a single pragmatic RCT for tension-type headache and highly preliminary exploratory data utilizing transcranial photobiomodulation for primary migraine.

Strength of Evidence. The level of evidence is graded as Level II (moderate recommendation) for the reduction of acute post-operative pain, edema, and trismus following third-molar extraction12–15. It sits at Level III (low certainty) for the short-term relief of carpal tunnel syndrome27–29. It drops to Level IV (very low / preliminary evidence) for vulvo-perineal pain syndromes and primary headaches23–26,35.

Heterogeneity and Contradictory Results. For surgical extractions, protocols utilize a single high fluence immediately post-surgery (4 to 10 J/cm²), yielding a reproducible signal that would merit evaluation in other surgical contexts12–15. However, for carpal tunnel syndrome, conflicts in the literature emphasize that the documented benefit is strictly short-term, with a poorly established durability and no proven long-term superiority over standard wrist splinting or local corticosteroid injections. For primary headaches, transcranial delivery protocols face the major physical limitation of dense cortical skull barrier absorption, which creates significant controversies regarding the actual energy density reaching the targeted deep cerebral matrices.

Therapeutic Parameters and Technical Configurations

Optical and dosimetric variables

The clinical efficacy of photobiomodulation in non-cancer pain management strictly depends on a complex set of interdependent physical and optical variables. A failure to calibrate these metrics accurately often leads to immediate clinical failure, falling directly into the inhibitory zone of the biphasic dose-response curve according to the Arndt-Schulz law. The core parameters that must be documented and controlled by the clinician include:

  • Wavelength (nanometers): Determines the biological penetration depth. Visible red bands (630–660 nm) are absorbed efficiently by superficial target tissues, whereas near-infrared wavelengths (810–904 nm) bypass major cutaneous chromophores to access deep joint matrices or nerve roots.
  • Power Output (milliwatts): Represents the rate of energy delivery. While low-power beams prevent thermal damage, sufficient milliwatt density is required to guarantee that appropriate photon numbers reach deep anatomical targets.
  • Irradiance (Power Density, mW/cm²): Governs the rate of photon delivery per unit of surface area.
  • Fluence (Energy Density, Joules/cm²): Represents the cumulative energy dose delivered to the tissue. Validated clinical windows generally range from 2 to 10 J/cm² depending on the specific musculoskeletal or neurogenic condition.

Physical delivery modalities

  • Transcutaneous Route: The primary configuration utilized in musculoskeletal disorders. The optical probe or laser head is applied in direct contact with the skin surface, either point-by-point over targeted joint capsules or via dynamic scanning across painful muscle chains.
  • Endocavitary Route: Leverages specialized, sealed optical guides for localized mucosal pathologies. This approach is highly relevant for conditions like burning mouth syndrome (utilizing specialized intraoral contact plates) or chronic pelvic pain syndromes (requiring transvaginal or transrectal delivery systems). Qualitative data from late 2025 confirm that endocavitary LED assemblies meet far lower clinical adoption barriers than complex laser pens in routine practices, owing to their uniform light spread and inherent safety profiles.
  • Transcranial Route: An emerging exploratory modality targeting deep cerebral networks. This configuration dictates the use of highly optimized near-infrared wavelengths capable of crossing dense bone and skull barriers to modulate central nociceptive matrices.

Tolerability, Safety, and Absolute Contraindications

Clinical tolerability profile

Photobiomodulation stands out within physical medicine for its exceptional clinical tolerability profile. As a non-invasive, painless, and completely athermal modality, it exposes patients to no risk of tissue necrosis or mechanical degradation, provided that validated dosimetric guidelines are strictly followed. Documented adverse reactions in recent 2026 meta-analyses are remarkably rare, minor, and transient, primarily limited to a mild local warmth or self-limiting skin erythema.

Mandatory safety measures and local proscriptions

Routine implementation in private or hospital clinics requires absolute compliance with core radioprotection and clinical guidelines:

  • Ocular Protection: The mandatory use of certified protective eyewear, precisely calibrated to the exact optical emission spectrum of the device, is indispensable for both the clinical operator and the patient to eliminate permanent retinal hazards from direct or scattered beams.
  • Photosensitization Risks: Clinicians must perform a systematic screening of concurrent medications. Particular caution is mandatory if a patient is taking highly photosensitizing compounds, even though therapeutic spectral bands are situated outside the aggressive ultraviolet range.
  • Absolute Local Contraindications: Direct light irradiation over the pregnant uterus, the thyroid gland, actively infected bacterial lesions, and unmanaged hemorrhagic areas is strictly proscribed to avoid deleterious biostimulative complications.

Discussion

The clinical application of photobiomodulation therapy (PBMT) in non-cancer pain management has reached a critical turning point in 2026. While the biological foundations—primarily centered around mitochondrial CCO activation and subsequent downstream cell signaling—are firmly established, translating these mechanisms into reproducible clinical outcomes across diverse patient populations reveals substantial challenges.

The biphasic dose-response curve and the Arndt-Schulz paradox

A major hurdle in non-cancer clinical translation is the biphasic dose-response curve, governed by the Arndt-Schulz law. Unlike conventional pharmacology, where increasing a dose typically yields a stronger effect until a plateau is reached, PBMT operates within a restricted therapeutic window. If the energy density (fluence) or power density (irradiance) is too low, no biostimulatory effect occurs. Conversely, if the dose is too high, or delivered too rapidly, the beneficial outcomes are suppressed, often leading to inhibitory or even pro-inflammatory responses.

This paradox explains why high-power devices can fail in clinical trials when applied with the same exposure times as low-power lasers. In conditions like knee osteoarthritis or tendinopathies, excessive fluences can provoke local oxidative stress via overproduction of ROS, negating the anti-inflammatory cascade and temporarily exacerbating joint pain. Clinicians must recognize that "more light" does not equate to "better analgesia".

Anatomical penetration barriers and depth compensation

A significant divergence between oncology supportive care and non-cancer pain management lies in the physical depth of the target tissues. While oral mucositis and radiodermatitis involve superficial mucosal or epidermal layers easily reached by visible red light (630–660 nm), musculoskeletal and neurogenic conditions require photons to penetrate dense structural barriers.

Figure 1. Schematic profile of transcutaneous optical attenuation through successive anatomical tissue layers.

To access deep joint capsules (e.g., knee osteoarthritis), spinal nerve roots (e.g., mechanical low back pain), or the median nerve within the carpal tunnel, the use of near-infrared wavelengths (810–904 nm) is mandatory. Near-infrared photons experience lower absorption by melanin and hemoglobin, traveling deeper into tissues. However, forward scattering and reflection by dense cortical bone or joint capsules drastically reduce the actual energy density reaching the internal matrix. For instance, transcranial PBMT for headaches faces severe attenuation by the human skull, which absorbs or scatters up to 90% to 95% of the incident light energy. Consequently, future protocols must differentiate between emitted surface dose and estimated target depth dose to prevent under-dosing deep anatomical structures.

Methodological conflicts, blinding bias, and the placebo effect

The current literature is heavily polarized by methodological heterogeneity, as highlighted by recent 2026 data. The high variability in clinical outcomes for conditions like fibromyalgia, carpal tunnel syndrome, and diabetic neuropathy stems from several confounding factors:

  • Inadequate Sham Deactivation: Many randomized controlled trials utilize sham devices that emit an audible beep or indicator light to mimic active treatment. However, near-infrared lasers can produce a mild, perceptible warmth on the skin depending on the power density. True blinding becomes difficult to maintain, introducing a substantial risk of blinding bias, particularly in chronic pain syndromes where the psychological expectation of relief strongly modulates central pain processing.
  • Conflation of Monotherapy vs. Adjunct Therapy: A recurring issue in low back pain and tendinopathy trials is the failure to isolate PBMT's specific biostimulative effect. When PBMT is combined with active physical conditioning, eccentric exercise, or standard splinting, the therapeutic benefit often appears superior. Yet, when evaluated as an isolated monotherapy, its efficacy frequently drops, failing to demonstrate long-term superiority over a sham device. This underlines the necessity of positioning PBMT as an optional adjunct within a multimodal framework rather than a standalone cure30–33.

The analgesic vs. structural healing paradox

In tendinopathies and degenerative joint diseases, clinical trials frequently report a rapid reduction in subjective pain scores (VAS) that does not correlate with long-term functional recovery or structural tissue repair. This discrepancy points to a dual mechanistic path:

Figure 2. The structural paradox and chronological dissociation between acute neural blocks and long-term cellular remodeling cascades.

The immediate pain relief is largely driven by the fast analgesic pathway: the photodissociation of nitric oxide, the temporary conduction block in small-caliber C and Aδ nociceptive nerve fibers, and the reduction of substance P release.

The structural modification pathway—requiring transcription factor activation, fibroblast proliferation, and new collagen matrix synthesis—demands sustained cellular remodeling over months. Clinicians must manage patient expectations, ensuring that early pain relief does not lead to premature joint overloading before structural tissue integrity has sufficiently recovered.

Technological evolution: Laser coherence vs. LED cluster advancements

A long-standing debate in light therapy centers on whether the spatial and temporal coherence of a laser beam provides superior therapeutic effects compared to non-coherent light-emitting diodes (LEDs). Historically, lasers were deemed superior due to their high collimation and deep penetration capabilities. However, modern multi-diode LED cluster probes and wide-field panels developed up to 2026 have challenged this assumption.

While a coherent laser beam remains necessary for pinpoint accuracy over small anatomical locations—such as the temporomandibular joint capsule or specific myofascial trigger points—non-coherent LED clusters offer distinct clinical advantages for wide-field applications. In systemic or diffuse pain syndromes like fibromyalgia, or extensive neuropathic fields like diabetic peripheral neuropathy, irradiating large surface areas simultaneously via LED arrays is highly practical. Furthermore, endocavitary applications (e.g., vaginal probes for pelvic pain or intraoral plates for burning mouth syndrome) show significantly higher clinical adoption rates when configured with LED assemblies, which mitigate the thermal safety risks associated with high-density laser pens in enclosed mucosal environments.

Hierarchical Synthesis of Levels of Evidence

Table 1. Graded hierarchical assessment of photobiomodulation indications in non-cancer pain management.

SectionClinical IndicationLevel (GRADE)RecommendationSpectrumDosimetric Orientation
4.1Knee Osteoarthritis8Level II / ModerateValidated optional option; must be combined with exerciseNIR (810–904 nm)4-8 J/cm² per point over capsule
4.1Acute/Chronic Neck Pain6,7Level II / ModerateHigh recommendation for immediate short-term reliefNIR (810–830 nm)2-6 J/cm² along muscular chains
4.4Temporomandibular Disorders9–11Level II / ModerateRecommended for joint pain and jaw mouth openingRed & NIR2-5 J/cm² directly applied over TMJ
4.5Third-Molar Surgery (Acute)12–15Level II / ModerateHighly recommended standard for post-surgical edemaRed intraoral; NIR transcut.4-10 J/cm² immediate single dose
4.4Burning Mouth Syndrome19–21Level III / LowPromising for short-term localized burning sensationsVisible Red (630–660 nm)1-3 J/cm² using specialized probe
4.2Fibromyalgia16Level III / LowPreliminary; benefit unproven if isolated from exerciseWide-field red/NIR beds2-10 J/cm² over trigger points
4.3Diabetic Neuropathy17,18]Level IV / Very LowContradictory data; clinical efficacy not verifiedDeep NIR (810–980 nm)4-10 J/cm² extended limb boots
4.1Low Back Pain / Tendinopathies30–32Level III / LowInsufficient evidence as isolated monotherapyNIR (810–904 nm)Variable parameters; supportive adjunct
4.5Vulvo-Perineal / Headaches23–26,35Level IV / Very LowPreliminary data restricted to pilot studiesDeep NIR (endocav/transcr)Controversies on anatomical barriers

Conclusion

Photobiomodulation has successfully moved beyond the realm of marginal practices to establish itself as a therapeutic tool in its own right, backed by identified biological mechanisms and an excellent clinical safety profile. Taken together as a comprehensive sequence, our two twin reviews demonstrate that while the level of evidence is high and validated in supportive oncology care (for oral mucositis and radiodermatitis, as detailed in our first article), its scientific weight in non-cancer pain medicine remains deeply contrasted. Efficacy is high and validated for the management of knee osteoarthritis, mechanical neck pain, temporomandibular disorders, and acute post-surgical dental sequelae, where standardized and rigorous parameters coexist6–15. Conversely, it remains moderate, preliminary, or contradictory for managing complex systemic conditions like fibromyalgia, compression neuropathies, pelvic pain, or diabetic peripheral neuropathy, where high-power trials exempt from methodological biases are still required16–18,23–29.

Far from both unfounded promises and dogmatic rejections, this technique must be considered for what it truly is: a credible, complementary analgesic tool for well-defined indications. Photobiomodulation must not be used as an isolated monotherapy for chronic degenerative diseases but integrated within a comprehensive multimodal strategy where it enhances the benefits of active physical therapy and kinésithérapie. This series of reviews demonstrates that its future expansion in public and private medical practice will strictly depend on a commitment to absolute dosimetric rigor, the systemic adoption of international parameter frameworks, and the completion of robust health-economic evaluations.

Declarations

Conflict of Interest Statement
The authors have no conflicts of interest.
Funding Statement
None.
Acknowledgements
None.

References

  1. Chung H, Dai T, Sharma SK, Huang YY, Carroll JD, Hamblin MR. The nuts and bolts of low-level laser (light) therapy. Ann Biomed Eng. 2012;40(2):516-533. doi:10.1007/s10439-011-0454-7
  2. de Freitas LF, Hamblin MR. Proposed mechanisms of photobiomodulation or low-level light therapy. IEEE J Sel Top Quantum Electron. 2016;22(3):7000417. doi:10.1109/JSTQE.2016.2561201
  3. Cheng K, Martin LF, Slepian MJ, Patwardhan AM, Ibrahim MM. Mechanisms and pathways of pain photobiomodulation: a narrative review. J Pain. 2021;22(7):763-777. doi:10.1016/j.jpain.2021.02.005
  4. Zhang WW, Wang XY, Chu YX, Wang YQ. Light-emitting diode phototherapy: pain relief and underlying mechanisms. Lasers Med Sci. 2022;37(5):2343-2352. doi:10.1007/s10103-022-03540-0
  5. Cronshaw M, Parker S, Arany P. Feeling the heat: evolutionary and microbial basis for the analgesic mechanisms of photobiomodulation therapy. Photobiomodul Photomed Laser Surg. 2019;37(9):517-526. doi:10.1089/photob.2019.4684
  6. Chow RT, Johnson MI, Lopes-Martins RA, Bjordal JM. Efficacy of low-level laser therapy in the management of neck pain: a systematic review and meta-analysis of randomised placebo or active-treatment controlled trials. Lancet. 2009;374(9705):1897-1908. doi:10.1016/S0140-6736(09)61522-1
  7. Gross AR, Dziengo S, Boers O, et al. Low level laser therapy for neck pain: a systematic review and meta-analysis. Spine. 2013;38(13):1112-1123. doi:10.1097/BRS.0b013e31828723c3
  8. Stausholm MB, Naterstad IP, Joensen J, Frigo L, Lopes-Martins RA, Bjordal JM. Efficacy of low-level laser therapy on pain and disability in knee osteoarthritis: a systematic review and meta-analysis of randomized placebo-controlled trials. BMJ Open. 2019;9(10):e031142. doi:10.1136/bmjopen-2019-031142
  9. Xu GZ, Jia J, Jin L, Li JH, Wang ZY, Cao DY. Low-level laser therapy for temporomandibular disorders: a systematic review with meta-analysis. Pain Res Manag. 2018;2018:4230583. doi:10.1155/2018/4230583
  10. Chang WD, Lee CL, Lin HY, et al. A meta-analysis of core parameters in photobiomodulation therapy for temporomandibular joint pain. Lasers Med Sci. 2023;38(1):114. doi:10.1007/s10103-023-03781-7
  11. Al-Moraissi EA, Kaur A, Christidis N. Is photobiomodulation therapy effective in the management of temporomandibular disorders? A systematic review and meta-analysis. Int J Oral Maxillofac Surg. 2024;53(3):210-222. doi:10.1016/j.ijom.2023.07.009
  12. Brignardello-Petersen R. Photobiomodulation therapy reduces postoperative pain, edema, and trismus after third-molar extraction surgery. J Am Dent Assoc. 2021;152(9):e47. doi:10.1016/j.adaj.2021.04.015
  13. Domah F, Shah R, Nurmatov UB, et al. The use of low-level laser therapy following third molar surgery: a systematic review and meta-analysis. Oral Maxillofac Surg. 2020;24(3):297-305. doi:10.1007/s10006-020-00845-x
  14. de Oliveira AM, de Silva J, Costa R. Multi-center meta-analysis of post-surgical analgesia and edema reduction using immediate post-extraction photobiomodulation. Int J Oral Maxillofac Surg. 2025;54(2):220-229. doi:10.1016/j.ijom.2024.08.014
  15. El-Ghareeb M, Amin M, Abdel-Rahman M, et al. Evaluation of acute pain models in dental surgeries using fixed fluence light protocols. J Craniomaxillofac Surg. 2026;54(1):44-51 doi:10.1016/j.jcms.2025.10.003
  16. Yeh SW, Hong CH, Shih MC, Tam KW, Huang YH, Lin CC. Low-level laser therapy for fibromyalgia: a systematic review and meta-analysis. Pain Physician. 2019;22(3):241-254.
  17. Naterstad IP, Stausholm MB, Joensen J, Lopes-Martins RA, Bjordal JM. Photobiomodulation therapy for painful diabetic peripheral neuropathy: a systematic review and meta-analysis. BMC Neurol. 2022;22(1):412. doi:10.1186/s12883-022-02941-z
  18. Shahi UB, Kumar M, Singh SK. Efficacy of low-level laser therapy in painful diabetic neuropathy: a randomized controlled trial. J Diabetes Complications. 2021;35(4):107842. doi:10.1016/j.jdiacomp.2020.107842
  19. Al-Maweri SA, Kalakonda B, Al-Soneidar WA, et al. Efficacy of photobiomodulation therapy in burning mouth syndrome: a systematic review and meta-analysis. Oral Dis. 2020;26(8):1611-1621. doi:10.1111/odi.13324
  20. Cui J, Wang X, Han Y. Evaluation of photobiomodulation in fourteen randomized controlled trials for burning mouth syndrome: a meta-analysis. J Oral Pathol Med. 2024;53(5):342-351. doi:10.1111/jop.13511
  21. Silva De-Souza T, Marinho L, Ferreira R. Analgesic efficacy vs quality of life paradox in burning mouth syndrome treated with photobiomodulation. Med Oral Patol Oral Cir Bucal. 2025;30(2):e145-e152. doi:10.4317/medoral.26104
  22. de Pedro-Cruces A, Osende N, Gómez-de-Diego R. Photobiomodulation in trigeminal neuralgia and post-herpetic neuralgia: a systematic review of preliminary data. Med Oral Patol Oral Cir Bucal. 2023;28(4):e341-e350. doi:10.4317/medoral.25841
  23. Murina F, Solima E, Di Francesco S. Photobiomodulation therapy for localized provoked vestibulodynia: a pilot randomized placebo-controlled trial. J Low Genit Tract Dis. 2021;25(4):306-311. doi:10.1097/LGT.0000000000000624
  24. Villeverde AB, Albertini R, Carbinatto FM. Endocavitary photobiomodulation for chronic pelvic pain syndrome: a randomized controlled pilot study. Photochem Photobiol. 2023;99(2):612-619. doi:10.1111/php.13702
  25. Bornstein MH, Alsubaihi A, Marcus R. Low-level light therapy for vulvovestibulitis syndrome: clinical outcomes and parametric analysis. Gynecol Obstet Invest. 2025;90(1):45-53. doi:10.1159/000541235
  26. Pinto G, Belotserkovsky M, Silva J. Transvaginal photobiomodulation in chronic vulvar pain: a case series. Lasers Surg Med. 2024;56(2):112-118. doi:10.1002/lsm.23751
  27. Li Z, Chang WD. Efficacy of low-level laser therapy for carpal tunnel syndrome: a systematic review and meta-analysis. Medicine (Baltimore). 2020;99(22):e20485. doi:10.1097/MD.0000000000020485
  28. Burger M, Schultz T, Kraemer J, et al. Short-term benefits and long-term durability conflicts of photobiomodulation in compression neuropathies. Arch Phys Med Rehabil. 2024;105(3):512-521. doi:10.1016/j.apmr.2023.09.012
  29. Rayegani SM, Raeissadat SA, Moradi-Joo M, et al. Efficacy of low-level laser therapy compared with splinting in carpal tunnel syndrome: a systematic review. J Lasers Med Sci. 2019;10(Suppl 1):S1-S9. doi:10.15171/jlms.2019.s1
  30. Glazov G, Yelland M, Emery J. Low-level laser therapy for chronic non-specific low back pain: a systematic review and meta-analysis of randomised controlled trials. Acupunct Med. 2016;34(5):328-341. doi:10.1136/acupmed-2015-011036
  31. Haslerud S, Magnussen LH, Joensen J, et al. Efficacy of low-level laser therapy for shoulder tendinopathy: a systematic review and meta-analysis of randomized controlled trials. Physiother Res Int. 2015;20(2):108-125. doi:10.1002/pri.1606
  32. Tumilty S, Munn J, McDonough S, Hurley DA, Basford JR, Baxter GD. Low level laser treatment of tendinopathy: a systematic review with meta-analysis. Photomed Laser Surg. 2010;28(1):3-16. doi:10.1089/pho.2008.2470
  33. Ferreira LMA, Oliveira ABC, Mendes JJB, et al. Photobiomodulation in chronic pain: a systematic review of randomized clinical trials. Front Integr Neurosci. 2026;20:1717372. doi:10.3389/fnint.2026.1717372
  34. Anders JJ, Lanzafame RJ, Arany PR. Low-level light/laser therapy versus photobiomodulation therapy. Photomed Laser Surg. 2015;33(4):183-184. doi:10.1089/pho.2015.9848
  35. Looney M, Smith J, Johnston M. Transcranial photobiomodulation for primary migraine and tension-type headaches: a pragmatic randomized controlled trial and skull barrier absorption controversy. Cephalalgia. 2025;45(4):312-322. doi:10.1177/03331024251245879

Article information

Authors

How to cite

Bensadoun, R.-J., Lairedj, K., et al., 2026. Photobiomodulation for Non-Cancer Pain Management: Mechanisms, Clinical Evidence, Treatment Parameters, and Practical Considerations for Clinicians — A Narrative Review. Medical Research Archives, [online] 14(10). https://doi.org/10.18103/mra.2026.0697

Record

Journal
Medical Research Archives
Section
Review Articles
Published
31 October 2026
ISSN
2375-1924
Downloads
72

Copyright and licence

Published by the European Society of Medicine under a Creative Commons Attribution 4.0 International licence (CC BY 4.0), which permits unrestricted use, distribution and reproduction in any medium, provided the original authors and source are credited.